

A new journal in the field of ONCOLOGY

Clinical Communications-Oncology



Stay tuned to find out more!

Scheduled Launch: Jan 2014

Editors-in-Chief:

Gopala Kovvali, M.Phil, Ph.D, USA Stefan Glück, M.D, Ph.D, USA

Vision

Clinical Communications-Oncology (CCOnc) envisions to be a global journal for the dissemination of conventional and non-conventional outcomes from clinical, laboratory, translational and experimental medicine in the field of oncology.

Mission

- To provide a credible and innovative platform in oncology
- Dissemination of information and knowledge among clinicians, nurses, patients, clinical scientists, healthcare policy advisors and pharmaceutical industry.

Aims and Scope

Clinical Communications-Oncology (CCOnc) is a distinct journal in many ways. CCOnc acts as a gateway for the clinical and allied health research community and plays a role in the rapidly expanding global medical education needs. CCOnc also provides an opportunity to share clinical observations that are likely to pave the way for personalized medicine.

The path between a clinical observation and the development of a therapy is long. A professional publication like CCOnc is imminent to play a key role in the dissemination of new and intriguing information from the clinics and laboratories of established as well as upcoming clinical and allied health professionals. CCOnc will provide a focused platform for publishing case reports and clinical research outcomes in the field of oncology and related disciplines.

Clinical Communications-Oncology publishes articles in the field of oncology and related disciplines

Topics of interest to the journal are:

- Observations in the clinic / a clinical laboratory on an individual or group of individuals that serve as a teaching material for pathbreaking investigations.
- Original reports or critical reviews of procedures, clinical treatment protocols, which either lend additional support or challenge the status quo.
- · Reports that describe the following:
 - The unconventional and ingenuous management of commonly occurring diseases or new diseases in the developing countries.
 - Modified approaches to treat diseases that suit the local needs and conditions in different parts of the world.
 - Disease pathogenesis in diverse populations; e.g. pathogenesis of gastric cancer among different populations.
 - The link between genetic diversity, polymorphism, disease incidence, treatment response to specific drugs.
 - maximum Novel diagnostic or prognostic molecular and clinical markers.
 - A hypothesis or a concept that challenges the established diagnosis, treatment, genesis of a diseases.
 - $\ensuremath{\mathtt{m}}$ The less-known or unknown subclasses of oncology related diseases.
- Clinical study outcomes from phase I-IV trials, investigator initiated studies.
 Special interest to the journal will be articles that describe population pharmacodynamics, pharmacokinetics, safety profiles of drugs in the clinic or in development.

The publishing philosophy of CCOnc is to provide a ground where an unbiased and objective exchange of ideas, information, knowledge can occur for the benefit of medical and scientific advancement of researchers and the best health outcomes for the patients can emerge.

Sister Publications





Editorial Office:

Sylvester Comprehensive Cancer Center, University of Miami, Leonard M. Miller School of Medicine, Suite 3310, Miami, FL, 33136, USA. E-mail: editor@cconcology.com, Web: www.cconcology.com